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Implantable left ventricular assist device for patients with
postinfarction ventricular septal defect
Cristiano Faber, MD, Patrick M. McCarthy, MD, Nicholas G. Smedira, MD, James B. Young, MD, Randall C. Starling, MD,
and Katherine J. Hoercher, RN, Cleveland, Ohio
The mortality for patients with postinfarction ventricularseptal defect (VSD) remains high because of extensiveventricular infarction and cardiogenic shock.1 Attemptsto bridge patients with VSD to transplantation are com-
plicated by technical difficulties because of necrotic muscle at the
site of left ventricular apical cannulation and previously placed
patches for VSD repair. We report 2 patients with cardiogenic
shock after VSD repair who were bridged to transplant with
implantable left ventricular assist device (LVAD) support.
Clinical Summaries
PATIENT 1. A 57-year-old man was transferred 2 days after an
anterior wall myocardial infarction with a large left-to-right shunt
on an intra-aortic balloon pump and inotropic support. The anterior
VSD was repaired with a bovine pericardial patch similar to the
technique of David et al.2 The postoperative course was compli-
cated by ongoing cardiogenic shock, despite maximal inotropic
and intra-aortic balloon pump support. Despite no residual shunt,
the patient had impending multiple organ failure. Seven days after
VSD repair, a HeartMate pneumatic LVAD (Thermo Cardiosys-
tems, Inc, Woburn, Mass) was implanted. At the operation, the left
ventricle was opened at the apex, leaving the patch undisturbed on
the septum. The inflow cannula cuff was sutured to the apex of the
left ventricle with horizontal mattress sutures and buttressed with
a strip of felt, with the inflow cannula oriented toward the mitral
valve. The patient was weaned off inotropic drugs with right
ventricular function preserved. He was transferred to a nursing
floor, and the only postoperative complication was a Staphylococ-
cus aureus infection, which was successfully treated with antibi-
otics. LVAD explantation and cardiac transplantation were per-
formed on the 73rd day of LVAD support, and the patient was
discharged 10 days after transplantation. Five years after trans-
plantation, the patient is alive and well.
PATIENT 2. A 54-year-old man underwent emergency anterior
VSD patch closure and coronary artery bypass. His postoperative
convalescence was complicated by congestive heart failure, but the
patient eventually was transferred to a rehabilitation facility. He
was transferred to our hospital because of persistent congestive
heart failure and was listed for transplantation. He had progressive
deterioration requiring 2 inotropic drugs, and a Novacor LVAD
(World Heart Corp, Ottawa, Ontario, Canada) was implanted. The
left ventricular apex was opened, and the patch was left on the
septum. The inflow cannula was placed and secured with the same
technique used in patient 1. After a slow recovery caused by
cardiac cachexia, he was discharged from the hospital. His post-
LVAD course was complicated by a transient ischemic attack and
high panel-reactive antibody titers. On postoperative day 91 after
LVAD implantation, the patient underwent LVAD explantation
and cardiac transplantation. The patient was discharged home 13
days after transplantation and is alive and well 3 years after the
operation.
Discussion
In the postthrombolytic era the mortality of postinfarction VSD
continues to be high: 94% at 30 days if treated medically and 47%
when treated surgically.3 The most dreaded complication is pump
failure or cardiogenic shock, which is the single most important
determinant of operative mortality.1,2 Patch closure of the VSD
can effectively close the defect and eliminate the shunt. However,
for patients with extensive infarction and pump failure, there is a
need for an effective mechanical support strategy, and external
ventricular assist devices have been successfully used, maintaining
more physiologic hemodynamics with minimum doses of drugs.4
To our knowledge, use of an implantable LVAD for postinfarction
VSD has not been previously reported.
Initially, patients with acute myocardial infarction (AMI) were
not thought to be good candidates for implantable LVAD insertion
because of the technical problems in securing the inflow cannula to
the necrotic infarcted myocardium.4,5 However, with experience,5
we found that patients with AMI could be safely bridged to
transplantation. On that basis, we elected to use the implantable
LVAD as a bridge to transplantation for patients with post-AMI
VSD instead of an external ventricular assist device. In particular,
these patients might have high preformed antibodies from prior
blood transfusions, and the implantable devices allow for hospital
discharge should the patient require prolonged support. Both pa-
tients demonstrated the typical pattern we have observed in pa-
tients with AMI involving the left main or left anterior descending
coronary artery. The right ventricle functioned well because it was
not involved in the infarction.
Although we have speculated that the total artificial heart
(TAH) might be the ideal strategy for patients with post-AMI
VSD,3 on the basis of our experience, the implantable LVAD
might be an equally effective strategy for bridge to transplantation
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or permanent implantation. Also, the AMI heart is not dilated and
might make proper fitting of the TAH difficult. However, post-
AMI ventricular arrhythmias might complicate LVAD patient
management, although this was not a problem for these 2 patients,
and theoretically favors TAH use.
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